Climb Bio, Inc. (NASDAQ:CLYM) Given Consensus Rating of “Buy” by Analysts

Climb Bio, Inc. (NASDAQ:CLYM) has been assigned an average rating of “Buy” from the fourteen research firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, ten have issued a buy rating and three have issued a strong buy rating on the company. The average 1-year price target among analysts that have covered the stock in the last year is $21.6364.

Several analysts have weighed in on the company. Chardan Capital assumed coverage on Climb Bio in a research report on Tuesday, May 5th. They set a “buy” rating and a $22.00 price objective on the stock. BTIG Research reaffirmed a “buy” rating and set a $19.00 price objective on shares of Climb Bio in a research report on Monday. Raymond James Financial assumed coverage on Climb Bio in a research report on Tuesday, March 10th. They set a “strong-buy” rating and a $25.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Climb Bio in a research report on Monday, April 20th. Finally, Truist Financial assumed coverage on Climb Bio in a research report on Tuesday, March 17th. They set a “buy” rating and a $17.00 price objective on the stock.

Institutional Trading of Climb Bio

Several large investors have recently bought and sold shares of CLYM. AQR Capital Management LLC bought a new stake in Climb Bio during the 1st quarter valued at approximately $27,000. Goldman Sachs Group Inc. bought a new stake in Climb Bio during the 1st quarter valued at approximately $147,000. Marshall Wace LLP bought a new stake in Climb Bio during the 2nd quarter valued at approximately $46,000. Qube Research & Technologies Ltd bought a new stake in Climb Bio during the 2nd quarter valued at approximately $43,000. Finally, Jane Street Group LLC purchased a new position in shares of Climb Bio during the second quarter valued at approximately $184,000. 69.76% of the stock is owned by institutional investors.

Climb Bio Price Performance

NASDAQ CLYM opened at $10.80 on Thursday. The stock has a market capitalization of $618.41 million, a PE ratio of -13.85 and a beta of 0.09. Climb Bio has a 1 year low of $1.16 and a 1 year high of $12.48. The business’s 50-day moving average is $9.79 and its 200 day moving average is $6.60.

Climb Bio (NASDAQ:CLYM) last posted its earnings results on Thursday, May 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.06. As a group, equities research analysts anticipate that Climb Bio will post -0.87 earnings per share for the current year.

Climb Bio Company Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.